‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

Article

Jaimy Lee Oct 13, 2026 1 Min Read

The Federal Trade Commission and seven states say Shkreli should be held in contempt

Join thousands of traders and investors. Discover how specific trading strategies work — and get started with your investment journey.

Create Account